Podocyte stress and detachment measured in urine are related to mean arterial pressure in healthy humans
- PMID: 32739208
- PMCID: PMC10440835
- DOI: 10.1016/j.kint.2020.03.038
Podocyte stress and detachment measured in urine are related to mean arterial pressure in healthy humans
Abstract
Hypertension-associated progressive glomerulosclerosis is a significant driver of both de novo and all-cause chronic kidney disease leading to end-stage kidney failure. The progression of glomerular disease proceeds via continuing depletion of podocytes from the glomeruli into the ultrafiltrate. To non-invasively assess injury patterns associated with mean arterial pressure (MAP), we conducted an observational study of 87 healthy normotensive individuals who were cleared for living kidney donation. Urine pellet podocin and aquaporin2 mRNAs normalized to the urine creatinine concentration (UPod:Creat ratio and UAqp2:Creat ratio) were used as markers of podocyte detachment and tubular injury, respectively. The ratio of two podocyte mRNA markers, podocin to nephrin (UPod:Neph) as well as the ratio of podocin to the tubular marker aquaporin2 (UPod:Aqp2) estimated the relative rates of podocyte stress and glomerular vs. tubular injury. The MAP was positively correlated with the UPod:Neph and UPod:Aqp2, thereby confirming the relationship of MAP with podocyte stress and the preferential targeting of the glomerulus by higher MAP. In multivariable linear regression analysis, both UPod:Neph and UPod:Creat, but not UAqp2:Creat or proteinuria, were both significantly related to a range of normal MAP (70 to 110 mm Hg). Systolic, as opposed to diastolic or pulse pressure was associated with UPod:Creat. Thus, higher podocyte stress and detachment into the urine are associated with MAP even in a relatively "normal" range of MAP. Hence, urine pellet mRNA monitoring can potentially identify progression risk before the onset of overt hypertension, proteinuria or chronic kidney disease.
Keywords: glomerulosclerosis; hypertension; podocyte.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures


References
-
- Fisher ND, Curfman G. Hypertension—a public health challenge of global proportions. Jama. 2018;320(17):1757–1759. - PubMed
-
- United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016.
-
- Klag MJ, Whelton PK, Randall BL, Neaton JD, et al. End-stage renal disease in African-American and white men: 16-year MRFIT findings. Jama. 1997;277(16):1293–1298. - PubMed
-
- Tozawa M, Iseki K, Iseki C, Kinjo K, et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41(6):1341–1345. - PubMed
-
- Hsu C. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials. Journal of human hypertension. 2001;15(2):99. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources